Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1992-08-24
1995-07-18
Ivy, C. Warren
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514333, 514337, 514438, 514441, 514448, 514471, 514472, 514473, 544124, 544146, 544152, 546153, 546174, 546176, 546180, 546256, 546283, 546284, 549 62, 549 66, 549 67, 549 68, 549 70, 549 71, 549 72, 549 73, 549 74, 549 75, 549 77, 549 78, 549 79, 549 80, 549473, 549475, 549476, 549477, 549478, 549480, 549483, 549484, 549487, 549488, 549491, 549492, 549494, 549495, 549496, 549497, 549498, 549499, 549500, 549501, 549502, A61K 31535, A01N 4340, C07D33332, C07D41300
Patent
active
054341515
ABSTRACT:
2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase.
A method to treat disorders mediated by PAF or leukotrienes is also disclosed, that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.
REFERENCES:
patent: 4539332 (1985-09-01), Biftu et al.
patent: 4757084 (1988-07-01), Biftu et al.
patent: 4910206 (1990-03-01), Houlihan
patent: 4916145 (1990-04-01), Tilley et al.
patent: 4959361 (1990-09-01), Walser
patent: 4987132 (1991-01-01), Mase et al.
patent: 4992428 (1991-02-01), Houlihan et al.
patent: 4996203 (1991-02-01), Biftu et al.
patent: 5001123 (1991-03-01), Biftu et al.
Biftu, T., et al., "Confirmation and Activity of Tetrahydrofuran Lignans and Analogues as Specific Platelet Activating Factor Antagonists," J. Med. Chem. vol., 29, No. 10 (1986) pp. 1917-1921.
Corey, E. J., et al., "Dual Binding Modes to the Receptor for Platelet Activating Factor (PAF) of Anti-PAF Trans-2,5-Diarylfurans," Tetrahedron Letters, vol. 29, No. 24 (1988) pp. 2899-2902.
Ponpipom, M. M., et al., "(.+-.)-TRANS-2-(3-Methylsulfonyl-4-Propoxyphenyl)-5-(3,4,5-Trimethoxyphen yl)Tetrahydrofuran (L-659,989), A Novel, Potent PAF Receptor Antagonist," Biochemicals and Biophysical Research Communications, vol. 150, No. 3 (1988) pp. 1213-1220.
Bartroli, J., J. Med. Chem. vol. 34 (1991) pp. 3328-3334.
Carlcellar, E., et al., J. Med. Chem., vol. 35 (1992) pp. 676-683.
Crawley, G. C., "Methoxytetrahydrodyrans, A New Series of Selective and Orally Potent 5-Lipoxygenase Inhibitors," J. Med. Chem., vol. 35, No. 14 (1992) pp. 2600-2609.
Musser, J. H., et al., "5-Lipoxygenase: Properties, Pharmacology and the Quinolinyl(bridge)aryl Class of Inhibitors," J. Med. Chem., vol. 35, No. 14 (1992) pp. 2502-2524.
Guthrie, R. W., et al., "Propenyl Carboxamide Derivatives As Antagonists of Platelet Activating Factor," J. Med. Chem., vol. 33 (1990) pp. 2856-2864.
Graham, D. W., et al., "1,3-Diarylcyclopentanes: A New Class of Potent PAF Receptor Antagonists," MEDI (1989).
Lave, D. et al., "Pyrrolo[1, 2-c]Thiazole Derivatives Potent PAF Receptor Antagonists" Drugs of the Future, vol. 14, No. 9 (1989) pp. 891-898.
Ogiso, A., et al., "The Structure of Futoenone, A Novel Spiro-Cyclohexadienone Derivative," Tetrahedron Letters, No. 16, (1968) pp. 2003-2008.
Ogiso, A., et al., "The Structure and Total Synthesis of Futoenone, a Constitute of Piper futokadzura SIEB. et ZUCC," Chem. Pharm. Bull., vol. 18, No. 1 (1970) pp. 105-114.
Ponpipom, M. M., et al., "Structure-Activity Relationships of Kadsurenone Analogues," J. Med. Chem., vol. 30 (1987) pp. 136-142.
Shen, T. Y., "Characterization of a Platelet-Activating Factor Receptor Antagonist Isolated from Halifenteng (Piper futokadsura); Specific Inhibition of in vitro and in vivo Platelet-Activating Factor-Induced Effects," Proc. Natl. Acad. Sci. USA, vol. 82, (Feb. 1985) pp. 672-676.
Weber, K. H., et al., "Hetrazepines as Antagonists of Platelet Activating Factor," Medicinal Research Reviews, vol. 9, No. 1 (Jan.-Mar. 1989) pp. 181-218.
Feinmark, S. J., "Leukotriene C.sup.4 Biosynthesis during Polymorphonuclear Leukocyte-Vascular Cell Interactions," Methods in Ezymology, vol. 187, pp. 559-560 (1990).
Hwang, S., "Specific Receptors of Platelet-Activating Factor, Receptor Heterogeneity, and Signal Transduction Mechanisms," J. Lipid Mediators, vol. 2 (1990) pp. 123-158.
McColl, S. R., "Determination of 5-Lipoxygenase Activity in Human Polymorphonuclear Leukocytes Using High-Performance Liquid Chromatography," J. Chromatography, vol. 378 (1986) pp. 44-449.
O'Donnell, M., et al., "Comparison of the Pulmonary Pharmacology of Leukotrienes and PAF: Effects of their Antagonists" Therapeutic Approaches to Inflammatory Diseases Proceedings of the Fourth International Conference of the Inflammatory Research Association, Oct. 23-27, 1988, White Haven, Pa., p. 169.
Page, C., et al., "PAF: New Antagonists New Roles in Disease and a Major Role in Reproductive Biology," 3rd International Conference on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids, Tokyo, Japan, May 8-12, 1989.
Shen, T. Y., et al., "The Chemical and Biological Properties of PAF Agonists, Antagonists, and Biosynthetic Inhibitors," Platelet-Activating Factor and Related Lipid Mediators, Plenum Press, New York, N.Y., pp. 153-190 (1985).
Cai Xiong
Hussoin Sajjat
Hwang San-Bao
Killian David
Shen T. Y.
Covington Raymond
CytoMed, Inc.
Ivy C. Warren
LandOfFree
Compounds and methods for the treatment of disorders mediated by does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for the treatment of disorders mediated by, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for the treatment of disorders mediated by will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2419067